- RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
This study is testing a new drug, daraxonrasib, for people with a specific type of advanced lung cancer (non-small cell lung cancer, or NSCLC) that has a RAS gene change. It compares the new drug to an existing chemotherapy, docetaxel, to see if it works better or has fewer side effects.
For: NSCLC (Non-small Cell Lung Cancer) · Non-Small Cell Lung Cancer · NSCLCUnited States · Australia · Belgium - RecruitingPHASE3
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
This study is for people who have had surgery for pancreatic cancer. We are testing a new drug, daraxonrasib, to see if it can stop the cancer from coming back, compared to just being watched. It's to help see if this new treatment works better.
For: Pancreatic Cancer · PDAC · PDAC - Pancreatic Ductal AdenocarcinomaUnited States · Puerto Rico · United Kingdom